An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Pfizer is licensing a promising investigational cancer medicine from a smaller company. This move improves the drugmaker's ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

The US’s policy under the Second Donald Trump Administration has undergone major changes, with experts saying that America is ...

Western drugmakers, investors increasingly aim to acquire Chinese compounds.

Pfizer has struck a massive $1.25 billion deal with China’s 3SBio to license a promising cancer drug, beefing up its oncology ...

Bispecific anti-PD1/VEGF remains one of the hottest topics in the oncology field. Click here for a detailed analysis.

At the heart of the deal is an anti-Claudin18.2 antibody-drug conjugate being developed for solid tumors, including gastric ...